DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
80 hedge funds and large institutions have $565M invested in DICE Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 17 reducing their positions, and 13 closing their positions.
375% more call options, than puts
Call options by funds: $5.32M | Put options by funds: $1.12M
94% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 17
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
5% more funds holding
Funds holding: 76 → 80 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11% less capital invested
Capital invested by funds: $637M → $565M (-$72.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27M |
| 2 |
BlackRock
New York
|
+$14.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.7M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.62M |
| 2 |
PA
Perceptive Advisors
New York
|
-$7.97M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.61M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.88M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.56M |
DICE Hedge Fund Activity: Q2 2022 in Review
80 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q2 2022, worth a combined $565M — down 11% from $637M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DICE positions and 13 closed out — a net gain of 6 holders — while 33 added to existing stakes and 17 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $27M. The largest seller was Eventide Asset Management, cutting an estimated $8.62M.
- 80 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q2 2022, up from 76 in Q1 2022.
- Funds reported $565M of DICE Therapeutics, Inc. Common Stock stock for Q2 2022, down 11% quarter-over-quarter.
- 19 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q2 2022 and 13 closed out, a net change of +6 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q2 2022 was Fidelity Investments, an estimated $27M added.
- The largest DICE Therapeutics, Inc. Common Stock seller in Q2 2022 was Eventide Asset Management, an estimated $8.62M sold.
Based on aggregated 13F filings for Q2 2022.